|
Decision Resources' analysts are the leading experts on various healthcare issues. From specific drug market analysis to insights on industry trends, Decision Resources' analysts are available to speak with journalists on almost any topic.
For media inquiries or to speak with an analyst, please contact:
Elizabeth Marshall
+1-781-296-2563
emarshall@dresources.com
July
[ Back to Top ]
July
1,
2008
A WEIGHT NEUTRAL ORAL ANTIDIABETIC DRUG WOULD EARN A 25 PERCENT PATIENT SHARE IN THE TYPE 2 DIABETES DRUG MARKET
Advantages in Efficacy and Safety Will Make Liraglutide the New Clinical Gold Standard Drug by 2011, According to a New Report from Decision Resources
More...
June
[ Back to Top ]
June
26,
2008
BECAUSE OF ITS ABILITY TO GENERATE HIGHER TOTAL SALES IN THE UNITED STATES AND EUROPE, LUCENTIS WILL EARN CLINICAL GOLD STANDARD STATUS BY 2011 FOR THE TREATMENT OF DIABETIC RETINOPATHY
A Drug with Superior Efficacy to Avastin at Improving Visual Acuity When Used with Laser Photocoagulation Would Earn a 20 Percent Patient Share, According to a New Report from Decision Resources
More...
June
25,
2008
CHINA’S RENAL CELL CARCINOMA DRUG MARKET WILL GROW MORE THAN FIVE-FOLD BY 2012
Physician Treatment Patterns and Drivers Will Vary by Geographic Location, According to a New Report by Decision Resources
More...
June
24,
2008
RENAL CELL CARCINOMA DRUG MARKET WILL MORE THAN DOUBLE OVER THE NEXT DECADE, RISING FROM $625 MILLION IN 2007 TO NEARLY $1.6 BILLION IN 2017
Multikinase Inhibitors, Most Notably Pfizer’s Sutent, Will Continue to Dominate the Market, According to a New Report from Decision Resources
More...
June
19,
2008
NOVEL AGENTS WILL DRIVE THE HEPATITIS C VIRUS DRUG MARKET TO INCREASE NEARLY FIVE-FOLD TO MORE THAN $10 BILLION IN 2017
Hepatitis C Virus Market is One of the Most Active Areas of Infectious Disease Drug Development in Recent Years, According to a New Report from Decision Resources
More...
June
18,
2008
LEXAPRO IS THE LEADING SINGLE AGENT IN FIRST- AND SECOND-LINE PATIENT SHARE FOR THE TREATMENT OF GENERALIZED ANXIETY DISORDER
The Presence of Comorbid Depression Influences Physicians to Prescribe a Selective Serotonin Reuptake Inhibitor, According to a New Report from Decision Resources
More...
June
18,
2008
LUNDBECK MAINTAINING PRESENCE IN ALZHEIMER’S DISEASE MARKET THROUGH STRATEGIC AGREEMENT TO MARKET MYRIAD GENETICS’ FLURIZAN
Physician Education Will be a Critical Step in the Adoption of Emerging Alzheimer’s Disease Therapies, According to a New Report from Decision Resources
More...
June
17,
2008
GENERIC EROSION OF MARKET LEADING THERAPIES WILL CONSTRAIN GROWTH IN THE PARKINSON’S DISEASE DRUG MARKET OVER THE NEXT DECADE
Modest Market Growth Will be Driven by the Arrival of Once-Daily Formulations of Dopamine Agonists, According to a New Report from Decision Resources
More...
June
17,
2008
DECISION RESOURCES, INC. ACQUIRES MANHATTAN RESEARCH
Acquisition Expands Decision Resources, Inc.’s Portfolio to Include Global
Physician and Consumer Digital Market Research
More...
June
16,
2008
GOLIMUMAB AND ACTEMRA WILL BE TWO OF THE MOST SUCCESSFUL EMERGING NOVEL AGENTS IN THE RHEUMATOID ARTHRITIS DRUG TREATMENT MARKET
Among Currently Available Therapies, Enbrel and Humira Will Continue to Dominate the Market Through 2017, According to a New Report from Decision Resources
More...
June
12,
2008
A DRUG WITH EFFICACY SUPERIOR TO THAT OF XENICAL AT INDUCING WEIGHT LOSS WOULD EARN A 40 PERCENT PATIENT SHARE IN THE OBESITY DRUG MARKET
Advantages in Efficacy and Delivery Will Make Qnexa the New Clinical Gold Standard Drug by 2011, According to a New Report from Decision Resources
More...
June
11,
2008
A DRUG WITH EFFICACY SUPERIOR TO THAT OF REMICADE AT INDUCING CLOSURE AND HEALING OF FISTULAS WOULD EARN A 30 PERCENT PATIENT SHARE IN THE CROHN’S DISEASE DRUG MARKET
Ustekinumab Will Earn a 5.4 Percent Patient Share by 2012, According to a New Report from Decision Resources
More...
June
10,
2008
THE MONOCLONAL ANTIBODIES DRUG MARKET FOR THE TREATMENT OF CANCER WILL MORE THAN DOUBLE TO $16.7 BILLION BY 2016
Market Will be Driven by Increasing Use of Established Agents That Include Avastin, Erbitux, Rituxan/MabThera, According to a New Report from Decision Resources
More...
June
9,
2008
EMERGENCE OF DRUGS FROM ELAN/WYETH, ELI LILLY, MYRIAD GENETICS AND MEDIVATION WILL DRIVE THE ALZHEIMER’S DISEASE DRUG MARKET TO NEARLY TRIPLE BY 2017
Sales of Currently Dominant Acetylcholinesterase Inhibitors Will Decrease by Nearly Half Over the Next Decade, According to a New Report from Decision Resources
More...
June
3,
2008
DESPITE AVAILABILITY OF NUMEROUS GENERIC ANTIDEPRESSANTS, FOREST LABORATORIES’ LEXAPRO RETAINS LEADERSHIP AMONG FIRST-LINE THERAPIES IN THE TREATMENT OF MAJOR DEPRESSION
Wyeth’s Pristiq to Benefit from Key Change in Physicians’ Prescribing Patterns, According to a New Report from Decision Resources
More...
June
3,
2008
GENERIC EROSION WILL CONSTRAIN PROSTATE CANCER DRUG MARKET, RESULTING IN ANNUAL MARKET GROWTH OF LESS THAN 2 PERCENT THROUGH 2012
However, Annual Market Growth Will Increase to 4.5 Percent from 2012 to 2017 Due to Emergence of Premium-Priced Drugs, According to a New Report from Decision Resources
More...
June
2,
2008
FLORIDA IS THE STATE WITH THE HIGHEST NUMBER OF TYPE 2 DIABETICS WHO HAVE PRESCRIPTION DRUG COVERAGE BUT ARE CURRENTLY UNTREATED
Decision Resources Introduces the Only Healthcare Analytics Tool that Assesses the Number of Insured Patients Who Have a Specific Disease, but Are Untreated
More...
June
2,
2008
DRIVEN BY THE USE OF PREMIUM-PRICED BRANDED AGENTS, THE HIV DRUG MARKET WILL EXPERIENCE ROBUST ANNUAL GROWTH THROUGH 2012
New Products From Novel Drug Classes Are Addressing Key Unmet Needs for Highly Treatment-Experienced Patients, According to a New Report from Decision Resources
More...
May
[ Back to Top ]
May
29,
2008
ORAL DRUG FROM NOVARTIS/MITSUBISHI TANABE WILL CAPTURE THE LARGEST MARKET SHARE OF ALL EMERGING MULTIPLE SCLEROSIS THERAPIES IN 2017
Overall Market Growth Will be Driven by Launch of Nine Emerging Therapies, Including Five Oral Agents, According to a New Report from Decision Resources
More...
May
28,
2008
EMERGING COMBINATION THERAPIES, INCLUDING DRUGS FROM NOVARTIS/SCHERING-PLOUGH AND GLAXOSMITHKLINE/THERAVANCE WILL DRIVE THE COPD DRUG MARKET TO MORE THAN $11 BILLION IN 2017
Prevalent COPD Population Will Rise by Nearly 19 Percent as a Result of Increased Diagnosis Rates, According to a New Report from Decision Resources
More...
May
28,
2008
CHINA’S TYPE 2 DIABETES DRUG MARKET WILL MORE THAN TRIPLE BY 2012
New Entries to China Drug Market to Garner More Than $270 Million in Combined Sales, According to a New Report by Decision Resources
More...
May
21,
2008
NOVEL GLYCOPEPTIDES AND CEPHALOSPORINS WILL DRIVE THE HOSPITAL-ACQUIRED INFECTIONS DRUG MARKET THROUGH 2017
Antibacterial Drug Development Faces Many Challenges Including Heightened Regulatory Scrutiny and Increasingly Stringent Reimbursement Policies, According to a New Report from Decision Resources
More...
May
19,
2008
INCREASED COMPETITION, GENERIC EROSION AND COST CONSCIOUSNESS WILL CAUSE ASTHMA DRUG MARKET TO DECLINE TO $10.1 BILLION IN 2017
However, Launch of New Agents Will Drive Growth in the Long-Acting Beta-Agonist/Inhaled Corticosteroid Class, According to a New Report from Decision Resources
More...
May
15,
2008
DAIICHI SANKYO/ELI LILLY’S EFFIENT AND ASTRAZENECA’S TICAGRELOR MAY OFFER ADVANTAGES IN THE TREATMENT OF POST-MYOCARDIAL INFARCTION
Considerable Opportunity Remains for an Antiplatelet Therapy that, Combined with Aspirin, Causes Less Bleeding than the Combination of Plavix/Iscover and Aspirin, According to a New Report from Decision Resources
More...
May
13,
2008
SIMVASTATIN LEADS PFIZER’S LIPITOR IN SECOND-LINE PATIENT SHARE FOR THE TREATMENT OF DYSLIPIDEMIA
Results from the ENHANCE Trial Impacting Physician Prescribing Patterns, According to a New Report from Decision Resources
More...
May
12,
2008
LAUNCHES OF AT LEAST 15 NEW BIOLOGIC THERAPIES BY 2017 WILL EXPAND TREATMENT OPTIONS FOR IMMUNE AND INFLAMMATORY DISEASES
High-Priced Emerging Immunomodulators Will Drive Robust Market Growth Over the Next Decade, According to a New Report from Decision Resources
More...
May
8,
2008
CURRENT AND EMERGING DRUGS HAVE NOT YET SHOWN AN ADVANTAGE IN SURVIVAL OVER VELCADE IN THE TREATMENT OF RELAPSED MULTIPLE MYELOMA
A Drug Used in Combination with Velcade That Could Improve Overall Survival Would Earn a 45 Percent Patient Share, According to a New Report from Decision Resources
More...
April
[ Back to Top ]
April
24,
2008
AVASTIN USED IN COMBINATION WITH DRUGS FROM BRISTOL-MYERS SQUIBB HAS ADVANTAGES IN SURVIVAL RATES OVER THE CURRENT SALES-LEADING THERAPY FOR ADVANCED OVARIAN CANCER
Avastin Used in Combination with Taxol and Paraplatin Will Become the Clinical Gold Standard Treatment by 2011, According to a New Report from Decision Resources
More...
April
24,
2008
CURRENT AND EMERGING INSOMNIA DRUGS HAVE MINIMAL ADVANTAGES OVER SANOFI-AVENTIS’S AMBIEN IN CAUSING THE ONSET OF SLEEP
However, Somaxon’s Silenor Will Replace Ambien as the Clinical Gold Standard for Insomnia in 2011, According to a New Report from Decision Resources
More...
April
22,
2008
CONCERN FROM DOCTORS REGARDING THE CARDIOVASCULAR SAFETY OF GLAXOSMITHKLINE’S AVANDIA INCREASES NINE-FOLD FOLLOWING PUBLICATION OF META-ANALYSIS
Nearly Three-Quarters of Physicians Have Switched Patients to Merck’s Januvia, According to a New Report from Decision Resources
More...
April
22,
2008
A DRUG THAT CARRIES A LOWER RISK OF WEIGHT GAIN THAN ASTRAZENECA’S SEROQUEL AND HAS ANTIMANIC AND ANTIDEPRESSANT EFFECTS WOULD EARN A 30 PERCENT PATIENT SHARE IN BIPOLAR DISORDER TREATMENT
Seroquel’s Successor, Seroquel XR, Will Earn a 16 Percent Patient Share in the Bipolar Disorder Market by 2016, According to a New Report from Decision Resources
More...
April
17,
2008
TIER STATUS IN PRIVATE INSURANCE PLANS FOR OTHER ANTIPSYCHOTIC DRUGS WILL REMAIN LARGELY UNCHANGED FOLLOWING THE PATENT EXPIRY OF JANSSEN’S RISPERDAL
However, Up to 20 Percent of Surveyed MCO Medicaid Plans Will Remove Branded Antipsychotics From Formularies, According to a New Report from Decision Resources
More...
April
17,
2008
BAYER/SCHERING-PLOUGH/SHIONOGI’S AVELOX HAS ADVANTAGES OVER LEVOFLOXACIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA
Superior Bacteriological Eradication and Activity Against Antibiotic-Resistant Pathogens Earn Avelox Gold Standard Status Through 2016, According to a New Report from Decision Resources
More...
April
16,
2008
PFIZER’S LYRICA DEMONSTRATES ADVANTAGES IN SUSTAINED EFFICACY OVER ELI LILLY’S SALES-LEADING CYMBALTA IN THE TREATMENT OF FIBROMYALGIA
Milnacipran Seen as Most Promising Emerging Drug, According to a New Report from Decision Resources
More...
April
9,
2008
NEW THERAPY BY MERCK IS POSITIONED TO EARN GOLD-STANDARD STATUS BY 2011 IN THE TREATMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
Emerging Agent GlaxoSmithKline’s Rezonic Demonstrating Efficacy for Delayed Chemotherapy-Induced Nausea and Vomiting, According to a New Report from Decision Resources
More...
April
8,
2008
A DRUG’S ABILITY TO ACHIEVE SUSTAINED VIRAL RESPONSE IN GENOTYPE 1 INFECTED PATIENTS IS THE MOST IMPORTANT DRIVER OF PRESCRIBING DECISIONS FOR HEPATITIS C VIRUS TREATMENT
Surveyed Physicians Will Use Novel Drugs From Schering-Plough and Vertex/Johnson & Johnson in 75 Percent of Non-Responder Patients, According to a New Report from Decision Resources
More...
April
7,
2008
MORE THAN HALF OF PATIENTS TREATED FOR BENIGN PROSTATIC HYPERPLASIA RECEIVE BOEHRINGER INGELHEIM’S FLOMAX AS FIRST-LINE THERAPY
Less Than 20 Percent of Patients Diagnosed with the Disease Receive Pharmacotherapy Within a Year of Their Diagnosis, According to a New Report From Decision Resources
More...
April
7,
2008
CURRENT AND EMERGING DRUGS HAVE NO ADVANTAGE OVER ENBREL IN INHIBITING/SLOWING THE PROGRESSION OF RHEUMATOID ARTHRITIS
Although Some Emerging Therapies Hold Promise, Enbrel Will Remain the Clinical Gold Standard Through 2016, According to a New Report from Decision Resources
More...
April
3,
2008
ASTELLAS/GLAXOSMITHKLINE’S VESICARE HAS ADVANTAGES OVER PFIZER’S DETROL LA/DETRUSITOL XL IN REDUCING EPISODES OF URGE URINARY INCONTINENCE
Superior Side-Effect Profile Earns Vesicare Gold Standard Status Over Sales-Leading Detrol LA/Detrusitol XL, According to a New Report from Decision Resources
More...
April
3,
2008
CHINA’S GASTRIC CANCER DRUG MARKET TO NEARLY TRIPLE BY 2012
Jiangsu Simcere’s Endostar and Merck KGaA’s Erbitux Are the Targeted Therapies Prescribed Most Often by Chinese Physicians for the Treatment of the Disease, According to a New Report by Decision Resources
More...
April
2,
2008
ASTRAZENECA’S RECENTIN PLUS FOLFOX4 TO EARN 10 PERCENT PATIENT SHARE IN THE TREATMENT OF COLORECTAL CANCER BY 2016
Physicians Indicate that Most Emerging Therapies Will Not Match the Current Gold Standard, According to a New Report from Decision Resources
More...
April
2,
2008
THE EFFECT OF DRUGS FROM NOVARTIS AND SANOFI-AVENTIS ON MORTALITY RATES WILL DRIVE PRESCRIBING DECISIONS IN HYPERTENSION TREATMENT
Novartis’s Exforge Will Remain the Clinical Gold Standard Through 2016, According to a New Report from Decision Resources
More...
March
[ Back to Top ]
March
27,
2008
THE MARKET FOR KINASE INHIBITORS IN CANCER TREATMENT WILL EXPERIENCE STAGGERING GROWTH, INCREASING FROM $769 MILLION IN 2006 TO MORE THAN $7.5 BILLION IN 2016
Emerging Drugs and Label Expansion of Currently Marketed Agents Will Drive Growth, According to a New Report from Decision Resources
More...
March
25,
2008
DRUG TREATMENT MARKET FOR OBESITY WILL INCREASE MORE THAN FIVE-FOLD, REACHING $2.7 BILLION IN 2016
Growth Will Be Driven by Novel Emerging Therapies, Including Drugs from Arena and Amylin, According to a New Report from Decision Resources
More...
March
20,
2008
ASTRAZENECA’S ZACTIMA WILL EARN ALMOST FIVE PERCENT PATIENT SHARE IN THE TREATMENT OF NON-SMALL-CELL LUNG CANCER BY 2016
Physicians Indicate that Most Promising Emerging Therapies Will Not Match the Current Gold-Standard Avastin/Taxol/Paraplatin Regimen’s Efficacy, According to a New Report from Decision Resources
More...
March
19,
2008
BY 2016, SIGNIFICANT GENERIC EROSION WILL CAUSE SALES OF DYSLIPIDEMIA DRUGS TO DECLINE BY $3.6 BILLION
Statins Will Continue to Dominate Market Despite Patent Expiries and Increased Use of Fixed-Dose Combinations, According to a New Report from Decision Resources
More...
March
19,
2008
ONE-THIRD OF U.S. PRIMARY CARE PHYSICIANS AND CARDIOLOGISTS DO NOT CURRENTLY PRESCRIBE TREATMENT TO MEET HDL CHOLESTEROL TARGETS AS RECOMMENDED BY NATIONAL GUIDELINES
Although Two-Thirds of Surveyed Physicians Anticipate an Increase in the Number of Patients Treated for Low HDL Over the Next Two years, 19 Percent of Surveyed MCOs Will Not Add Novel HDL Drugs to Their Formularies, According to a New Report from Decision Resources
More...
March
17,
2008
DECISION RESOURCES, INC. ACQUIRES FINGERTIP FORMULARY
Acquisition Expands Decision Resources, Inc.’s Offering to Include the Most Accurate, Comprehensive Formulary Solutions on the Market Today
More...
March
13,
2008
CURRENT AND EMERGING THERAPIES HAVE NO ADVANTAGE OVER PFIZER’S LYRICA IN THEIR EFFECT ON PATIENTS’ QUALITY OF LIFE IN THE TREATMENT OF DIABETIC NEUROPATHY
However, Owing to Safety and Delivery End Points, Drugs from Eli Lilly and Boehringer Ingelheim Will Remain as the Gold Standard Treatments, According to a New Report from Decision Resources
More...
March
11,
2008
TEVA PHARMACEUTICAL’S ALTERED PEPTIDE LIGAND COPAXONE BOASTS THE GREATEST PATIENT SHARE AMONG FIRST- AND SECOND-LINE THERAPIES FOR THE TREATMENT OF MULTIPLE SCLEROSIS
Lack of Flulike Side-Effects Drives Physician Prescribing of Copaxone over an Interferon-Beta Therapy, According to a New Report from Decision Resources
More...
March
10,
2008
NEWLY LABELED THERAPIES FOR NEUROPATHIC PAIN, INCLUDING DRUGS FROM PFIZER AND ELI LILLY, WILL DRIVE GROWTH IN THE CHRONIC PAIN DRUG MARKET
Following Recovery From Withdrawals of Two COX-2 Inhibitors, the Chronic Pain Drug Market Will Regain Momentum, According to a New Report from Decision Resources
More...
March
6,
2008
A DRUG WITH EFFICACY SUPERIOR TO THAT OF MEMANTINE WOULD EARN UP TO A 50% PATIENT SHARE IN THE MODERATE-TO-SEVERE ALZHEIMER’S DISEASE DRUG MARKET
A Drug’s Effect on Cognitive Decline is the Most Important Attribute Influencing Prescribing Decisions, According to a New Report from Decision Resources
More...
March
5,
2008
BRISTOL-MYERS SQUIBB AND OTSUKA PHARMACEUTICAL SPEND NEARLY TWICE AS MUCH ON PROMOTION AS OTHER DRUG COMPANIES IN THE ATYPICAL ANTIPSYCHOTICS MARKET YET GAIN MINIMAL COMPANY RECOGNITION AMONG PHYSICIANS
The New Brands & Strategies: Atypical Antipsychotics Report Provides Critical Commercial Analysis at the Market, Company, and Brand Level
More...
March
4,
2008
ALTHOUGH REMICADE AND HUMIRA ARE BEING INCREASINGLY PRESCRIBED FOR CROHN’S DISEASE AND ULCERATIVE COLITIS, INSURERS ARE SUBJECTING BOTH DRUGS TO MULTIPLE COST-CONTROL STRATEGIES
Nearly One-Third of Surveyed Managed Care Organizations Levy Coinsurance Charges and Other Protocols on Remicade and Humira, According to a New Report from Decision Resources
More...
March
3,
2008
ONCOLOGISTS DESPERATE FOR A DRUG THAT SIGNIFICANTLY INCREASES SURVIVAL RATES IN THE TREATMENT OF ADVANCED PANCREATIC CANCER
Experts are Cautiously Optimistic About Emerging Vaccines, According to a New Report from Decision Resources
More...
February
[ Back to Top ]
February
27,
2008
A ONCE-DAILY ORAL DRUG FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE THAT TREATS COPD-RELATED INFLAMMATION COULD ACHIEVE BLOCKBUSTER STATUS
Although Physicians Report Satisfaction with GlaxoSmithKline’s Advair and Boehringer Ingelheim/Pfizer’s Spiriva, Significant Need Remains for a Novel Anti-Inflammatory Drug, According to a New Report from Decision Resources
More...
February
26,
2008
COMPETITIVE ADVANTAGES POSITION GLAXOSMITHKLINE’S NOVEL COMBINATION THERAPY TO OVERTAKE AVODART AS THE CLINICAL GOLD STANDARD FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA BY 2011
A Drug with a Lower Incidence of Sexual Side Effects Would Require Improved Efficacy Over Existing Therapies, According to a New Report from Decision Resources
More...
February
25,
2008
UPTAKE OF BRANDED AGENTS WILL DRIVE THE SYSTEMIC LUPUS ERYTHEMATOSUS DRUG MARKET TO QUADRUPLE TO $1.4 BILLION IN 2016
Entry of Novel Therapies Including Rituxan/MabThera and Increased Uptake of CellCept Will Provide Effective Treatment Options, According to a New Report from Decision Resources
More...
February
22,
2008
IN COMBINATION WITH FOLFOX4, THE EFFECT OF ERBITUX AND AVASTIN ON SURVIVAL RATES WILL DRIVE PRESCRIPTION DECISIONS IN THE TREATMENT OF STAGE III COLON CANCER
Following its Approval, Erbitux Will Earn Gold-Standard Status in 2011, According to a New Report from Decision Resources
More...
February
19,
2008
JAPAN BACKS AWAY FROM MAKING REAL CHANGES TO ITS RX PHARMA PRICING MECHANISM
Proposed Changes Focus on Raising Price Premiums While Cutting Prices for Existing Drugs, According to a New Macroview Update from Decision Resources
More...
February
13,
2008
CENTOCOR/JANSSEN-CILAG’S USTEKINUMAB WILL BECOME THE GOLD STANDARD FOR PSORIASIS BY 2011
Competitive Advantages in Efficacy Will Drive Prescription Rates, According to a New Report from Decision Resources
More...
February
11,
2008
DESPITE ONCOLOGISTS’ WILLINGNESS TO PRESCRIBE AVASTIN FOR TREATMENT OF BREAST CANCER, THE FDA IS LIKELY TO RULE AGAINST THE PRODUCT ON FEBRUARY 23
Seventy-nine Percent of U.S. Oncologists Currently Use Avastin to Treat the Disease, According to a New Macroview Update from Decision Resources
More...
February
11,
2008
LIPITOR’S SUPERIOR EFFECT ON MORTALITY OVER SALES-LEADING PLAVIX IS DRIVING PRESCRIBING DECISIONS FOR THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE
Specialists Consider deCode Genetics’ DG-041 Positioned to Replace the Leading Antiplatelet Agent, According to a New Report from Decision Resources
More...
February
5,
2008
FLURIZAN’S EFFECT IN DELAYING PROGRESSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER’S DISEASE IS SUPERIOR TO THAT OF ARICEPT
Following its Launch in 2010, Myriad Genetics’ Flurizan Will Earn a 23% Patient Share in the United States, According to a New Report from Decision Resources
More...
February
4,
2008
EISAI/PFIZER’S ARICEPT OWNS A DOMINATING 42.4% PATIENT SHARE FOR FIRST-LINE TREATMENT OF ALZHEIMER’S DISEASE
Physician Familiarity and its Better Side-Effect/Safety Profile are Driving Aricept Prescription Rates, According to a New Report from Decision Resources
More...
January
[ Back to Top ]
January
30,
2008
PHYSICIANS STILL HOPEFUL ABOUT DESMOTEPLASE FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE DESPITE NEGATIVE RESULTS
Surveyed Neurologists Identify a Six-Hour Treatment Window as Area of Greatest Dissatisfaction, According to a New Report from Decision Resources
More...
January
28,
2008
NEW DRUG FROM SCHERING-PLOUGH/NOVARTIS WILL BECOME THE CLINICAL GOLD STANDARD FOR ASTHMA BY 2011
Advantages in Drug Delivery Will Drive Prescription Rates, According to a New Report from Decision Resources
More...
January
16,
2008
EFFICACY AND FAMILIARITY ARE KEY REASONS PHYSICIANS PRESCRIBE GLAXOSMITHKLINE’S ADVAIR FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ASTHMA
AstraZeneca’s Symbicort Is Gaining Favor Among Physicians for Use in the Treatment of the Diseases, According to New Reports from Decision Resources
More...
January
16,
2008
PATENT EXPIRIES OF KEY THERAPIES, INCLUDING DRUGS FROM GLAXOSMITHKLINE AND ROCHE, WILL CUT THE CHRONIC HEART FAILURE MARKET IN HALF BY 2016
Current Evidence on Emerging Therapies Shows No Significant Improvements Over Existing Drugs, According to a New Report from Decision Resources
More...
January
15,
2008
DRUG MARKETS IN COGNITIVE DYSFUNCTION WILL EXPERIENCE DRAMATIC TRANSFORMATION AS TOTAL SALES INCREASE FROM $300 MILLION IN 2006 TO $3.7 BILLION IN 2016
Launches of New Therapies Will Boost Diagnosis and Drug-Treatment Rates, According to a New Report from Decision Resources
More...
January
9,
2008
HURDLES ARE SIGNIFICANTLY RAISED FOR POTENTIAL BLOCKBUSTERS WHEN OPINIONS ON CLINICAL END POINTS VARY BETWEEN PHYSICIANS AND PAYERS
Views on End Points Differ Greatly for Some Indications, Including Major Depression, According to a New Report from Decision Resources
More...
|
